Skip to main content
AGEN
NASDAQ Life Sciences

Corrects Option Exchange Scope, Reducing Potential Dilution by 6.6M Shares

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
7
Price
$3.495
Mkt Cap
$145.54M
52W Low
$2.71
52W High
$7.34
Market data snapshot near publication time

summarizeSummary

Agenus Inc. filed a supplement to its proxy statement, correcting the number of options eligible for a proposed one-time exchange from 8.7 million to 2.1 million, significantly reducing the potential dilutive impact of the proposal.


check_boxKey Events

  • Material Correction to Proxy Statement

    The company filed a supplement to its April 30, 2026, proxy statement to correct an error regarding Proposal 4, the one-time option exchange.

  • Reduced Option Exchange Scope

    The number of options eligible for the exchange was corrected from an erroneous 8,697,165 to the accurate 2,103,891, a reduction of over 6.5 million options.

  • Lower Potential Dilution

    This correction significantly reduces the potential dilutive impact of the proposed option exchange on existing shareholders.

  • Tiered Option Exchange Structure

    Executive officers and non-employee directors will receive replacement options struck at a 50% premium to fair market value, while other employees and consultants will receive options at fair market value.


auto_awesomeAnalysis

This DEFA14A filing provides a material correction to a previously issued definitive proxy statement. The company significantly reduced the reported number of options eligible for a one-time exchange from 8.7 million to 2.1 million. This correction is important because it substantially decreases the potential dilutive impact of the proposed option exchange on existing shareholders. While the option exchange itself is a dilutive event, the reduction in its scope is a positive development, and the tiered pricing structure for executives (requiring 50% stock appreciation) aligns their incentives with shareholder returns.

At the time of this filing, AGEN was trading at $3.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145.5M. The 52-week trading range was $2.71 to $7.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed AGEN - Latest Insights

AGEN
May 13, 2026, 2:59 PM EDT
Filing Type: DEFA14A
Importance Score:
7
AGEN
May 11, 2026, 5:04 PM EDT
Filing Type: 10-Q
Importance Score:
9
AGEN
May 11, 2026, 8:52 AM EDT
Filing Type: 8-K
Importance Score:
9
AGEN
May 11, 2026, 8:46 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
AGEN
May 08, 2026, 11:30 AM EDT
Source: Reuters
Importance Score:
7
AGEN
Apr 30, 2026, 4:34 PM EDT
Filing Type: DEF 14A
Importance Score:
8
AGEN
Apr 20, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
8
AGEN
Apr 17, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
9
AGEN
Mar 26, 2026, 8:33 AM EDT
Source: Wiseek News
Importance Score:
8
AGEN
Mar 26, 2026, 8:24 AM EDT
Filing Type: 8-K
Importance Score:
8